REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 204 filers reported holding REATA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $2,241,296 | +51.1% | 58,997 | 0.0% | 0.11% | +32.1% |
Q3 2022 | $1,483,000 | -17.3% | 58,997 | 0.0% | 0.08% | -35.4% |
Q2 2022 | $1,793,000 | -7.2% | 58,997 | 0.0% | 0.13% | +54.8% |
Q1 2022 | $1,933,000 | -82.0% | 58,997 | -85.5% | 0.08% | -78.4% |
Q4 2021 | $10,713,000 | -84.7% | 406,264 | -41.5% | 0.39% | -82.9% |
Q3 2021 | $69,927,000 | -22.5% | 695,033 | +9.1% | 2.27% | +1.6% |
Q2 2021 | $90,203,000 | +20.6% | 637,344 | -15.0% | 2.23% | +35.4% |
Q1 2021 | $74,765,000 | -19.3% | 749,897 | 0.0% | 1.65% | -33.9% |
Q4 2020 | $92,702,000 | +75.0% | 749,897 | +37.9% | 2.50% | +62.4% |
Q3 2020 | $52,987,000 | -36.3% | 543,901 | +2.1% | 1.54% | -39.5% |
Q2 2020 | $83,140,000 | +8.3% | 532,878 | +0.2% | 2.54% | -18.3% |
Q1 2020 | $76,771,000 | -12.0% | 531,878 | +24.6% | 3.11% | +21.7% |
Q4 2019 | $87,234,000 | +527.0% | 426,719 | +146.3% | 2.56% | +372.6% |
Q3 2019 | $13,913,000 | – | 173,285 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 3,023,349 | $285,253,000 | 33.71% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 245,000 | $23,116,000 | 17.80% |
Prosight Management, LP | 124,965 | $11,790,000 | 5.94% |
Cormorant Asset Management, LP | 806,150 | $76,060,000 | 4.37% |
LBJ Family Wealth Advisors, Ltd. | 44,096 | $3,710,000 | 2.74% |
MORGENS WATERFALL VINTIADIS & CO INC | 34,350 | $3,241,000 | 2.23% |
Biondo Investment Advisors, LLC | 73,090 | $6,896,000 | 1.64% |
P.A.W. CAPITAL CORP | 15,000 | $1,415,000 | 1.53% |
EMERALD ADVISERS, LLC | 387,369 | $36,548,000 | 1.47% |
SPHERA FUNDS MANAGEMENT LTD. | 112,769 | $10,640,000 | 1.46% |